Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 10:15:1420331.
doi: 10.3389/fgene.2024.1420331. eCollection 2024.

Suppressor tRNAs at the interface of genetic code expansion and medicine

Affiliations
Review

Suppressor tRNAs at the interface of genetic code expansion and medicine

Aya Awawdeh et al. Front Genet. .

Abstract

Suppressor transfer RNAs (sup-tRNAs) are receiving renewed attention for their promising therapeutic properties in treating genetic diseases caused by nonsense mutations. Traditionally, sup-tRNAs have been created by replacing the anticodon sequence of native tRNAs with a suppressor sequence. However, due to their complex interactome, considering other structural and functional tRNA features for design and engineering can yield more effective sup-tRNA therapies. For over 2 decades, the field of genetic code expansion (GCE) has created a wealth of knowledge, resources, and tools to engineer sup-tRNAs. In this Mini Review, we aim to shed light on how existing knowledge and strategies to develop sup-tRNAs for GCE can be adopted to accelerate the discovery of efficient and specific sup-tRNAs for medical treatment options. We highlight methods and milestones and discuss how these approaches may enlighten the research and development of tRNA medicines.

Keywords: RNA therapeutics; genetic code expansion; nonsense mutations; premature termination codons; synthetic biology; tRNA; translation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

FIGURE 1
FIGURE 1
tRNA structure. (A) Secondary (cloverleaf) structure. The anticodon and elongation factor’s recognition bases are numbered. Bases 37 and 38 are known to increase PTC translation. (B) Tertiary (L-shaped) structure. (A,B) were created with BioRender.com and the tRNA crystal structure (PDB:1EVV), respectively.
FIGURE 2
FIGURE 2
Mechanistic differences and requirements between canonical, PTC, and GCE translation. For GCE translation, an orthogonal tRNA-aaRS pair is required. The orthogonal pair does not interact with endogenous tRNAs and aaRSs. The orthogonality requirement is achieved by introducing a tRNA-aaRS pair from an organism distinct from the host species. Created with BioRender.com.

Similar articles

Cited by

References

    1. Albers S., Allen E. C., Bharti N., Davyt M., Joshi D., Perez-Garcia C. G., et al. (2023). Engineered tRNAs suppress nonsense mutations in cells and in vivo . Nature 618 (7966), 842–848. 10.1038/s41586-023-06133-1 - DOI - PMC - PubMed
    1. Albers S., Beckert B., Matthies M. C., Mandava C. S., Schuster R., Seuring C., et al. (2021). Repurposing tRNAs for nonsense suppression. Nat. Commun. 12 (1), 3850. 10.1038/s41467-021-24076-x - DOI - PMC - PubMed
    1. Anastassiadis T., Köhrer C. (2023). Ushering in the era of tRNA medicines. J. Biol. Chem. 299 (10), 105246. 10.1016/j.jbc.2023.105246 - DOI - PMC - PubMed
    1. Anderson J. C., Schultz P. G. (2003). Adaptation of an orthogonal archaeal leucyl-tRNA and synthetase pair for four-base, amber, and opal suppression. Biochemistry 42 (32), 9598–9608. 10.1021/bi034550w - DOI - PubMed
    1. Anderson J. C., Wu N., Santoro S. W., Lakshman V., King D. S., Schultz P. G. (2004). An expanded genetic code with a functional quadruplet codon. Proc. Natl. Acad. Sci. U. S. A. 101 (20), 7566–7571. 10.1073/pnas.0401517101 - DOI - PMC - PubMed

LinkOut - more resources